The authorities of the city of Lübeck on Saturday, November 27, interrupted the campaign to vaccinate those who wish with the drug, which, apparently, did not have official registration. This is a coronavirus vaccine created by a local doctor and entrepreneur who owns Lübeck airport, professor of medicine Winfried Stöcker. If the suspicions of the police are justified, his act will be qualified as a violation of the drug law.
In April 2020, German media, including Der Spiegel magazine, told the story of Professor Stoecker, who developed a COVID-19 vaccine in his laboratory. Initially, he tested the drug on himself, friends and family members, later several dozen volunteers agreed to be vaccinated.
Winfried Stocker
In early September 2020, the doctor reported the results of his research to the Paul Ehrlich Institute (Das Paul-Ehrlich-Institut), which is responsible in Germany for vaccine registration and monitoring in this area. Stöcker asked for more trials to confirm the drug’s efficacy, but the institute responded by asking the prosecutor’s office.
On November 27, at Stöcker’s Lübeck airport, where the vaccination campaign took place, about 230 people gathered. More than 50 volunteers managed to inject before police and law enforcement intervened.
COVID-19 vaccine by Professor Stöcker
According to Stöcker himself, his drug is based on “a recombinant antigen that can be obtained easily and cheaply in a test tube.” The vaccine developed by the professor of medicine is comparable to that used against hepatitis A and B. A similar principle of action has a vaccine against the coronavirus of the American concern Novavax, an application for registration of which for use in the EU is currently being considered by the EMA regulator.
Since the antigen, unlike those used in mRNA and vector vaccines, multiplies not in the human body, but in a laboratory test tube, “there is no need to fear the uncontrolled spread of extraneous genetic information in the human body,” explains the German doctor.
However: Winfried Stöcker had no official approval, no research protocol, no preclinical clearance. In addition, as pointed out in his blog by veterinarian from Austria Petra Falb, Stöcker did not provide information about the possible contamination of his vaccine with extraneous viruses or mycoplasmas, which endangers the health of the volunteers.
Lack of full clinical trials of the vaccine
According to the inventor, his drug is 97% effective. However, these conclusions were obtained only on the basis of serological tests, according to which his probands developed antibodies to the SARS-CoV-2 virus. There have been no full-fledged clinical studies of the drug. In addition, so far the vaccine has not received reviews in any reputable medical publication.
In 1987, Stoecker founded Euroimmun, a company dedicated to the development of methods for the recognition of autoimmune and infectious diseases. It now has offices in 17 countries. In 2017, Stoecker sold Euroimmun to the American concern PerkinElmer for 1.2 billion euros.
See also:
.